Considerations for Microbiological Control Strategy during Oligonucleotide Drug Substance Manufacturing

Ensuring the quality and safety of synthetic oligonucleotide drug substances demands stringent microbial contamination control. While chemical synthesis inherently carries a lower risk compared with biological manufacturing, robust controls remain critical to minimize potential microbial proliferation at specific stages of the process. Given the limited regulatory guidance directly addressing oligonucleotides, effective contamination control strategies must be built upon thorough risk assessments and established best practices. This work, drawing on the collective expertise of the European Pharma Oligonucleotide Consortium, provides comprehensive recommendations for microbiological control in oligonucleotide manufacturing. Key points include facility design, environmental monitoring, equipment cleaning, in-process controls, and analytical methods. A thorough risk assessment and a holistic approach to microbial management are advocated. Detailed methodologies for risk evaluation, mitigation, and acceptance of residual risks are outlined. This strategic framework aims to proactively manage potential microbiological hazards, ensuring the consistent production of high-quality oligonucleotide therapeutics.